Advancis Pharmaceutical to Announce Third Quarter 2006 Financial Results on November 1, 2006
October 26 2006 - 9:00AM
PR Newswire (US)
Conference Call and Webcast to Follow GERMANTOWN, Md., Oct. 26
/PRNewswire-FirstCall/ -- Advancis Pharmaceutical Corporation
(NASDAQ:AVNC), a pharmaceutical company focused on developing and
commercializing novel anti-infective products, today announced it
will release results for the quarter ended September 30, 2006, on
Wednesday, November 1, 2006, before the market opens. A full text
copy of the release will be disseminated at that time. Edward M.
Rudnic, Ph.D., president and chief executive officer, will host a
conference call to discuss the results and other corporate
developments at 10:30 AM ET on Wednesday, November 1, 2006. Also
participating on the call will be Robert C. Low, vice president,
finance and CFO. To participate in the conference call, dial the
appropriate number below shortly before the 10:30 AM start time and
ask for the Advancis Pharmaceutical conference call hosted by Dr.
Rudnic. The teleconference dial-in numbers are as follows: Domestic
callers 1-800-813-8504 International callers 1-706-643-7752 The
conference call will be broadcast simultaneously and archived on
the Company's web site, http://www.advancispharm.com/. Investors
should go to the web site at least 15 minutes early to register,
download, and install any necessary audio software. A replay of the
call will be available on Wednesday, November 1, 2006, beginning at
12:30 PM ET and will be accessible until Wednesday, November 8,
2006, at 5:00 PM ET. The replay call-in number is 1-800-642-1687
for domestic callers and 1-706-645-9291 for international callers.
The access number is 9742528. About Advancis Pharmaceutical:
Advancis Pharmaceutical Corporation (NASDAQ:AVNC) is a
pharmaceutical company focused on the development and
commercialization of anti-infective drug products that fulfill
substantial unmet medical needs in the treatment of infectious
disease. The Company is developing anti-infective drugs based on
its novel biological finding that bacteria exposed to antibiotics
in front- loaded staccato bursts, or "pulses," are killed more
efficiently than those under standard treatment regimens. Based on
this finding, Advancis has developed a proprietary, once-a-day
pulsatile delivery technology called PULSYSTM. By examining the
resistance patterns of bacteria and applying its delivery
technologies, Advancis has the potential to redefine infectious
disease therapy and significantly improve drug efficacy, shorten
length of therapy, and reduce drug resistance versus currently
available antibacterial products. For more on Advancis, please
visit http://www.advancispharm.com/. DATASOURCE: Advancis
Pharmaceutical Corporation CONTACT: Bob Bannon, Vice President,
Investor Relations & Corporate Communications of Advancis
Pharmaceutical Corp., +1-301-944-6710, Web site:
http://www.advancispharm.com/
Copyright
Advancis (NASDAQ:AVNC)
Historical Stock Chart
From Jul 2024 to Aug 2024
Advancis (NASDAQ:AVNC)
Historical Stock Chart
From Aug 2023 to Aug 2024